Huntington's Disease (HD)

disease

HD — Huntington’s Disease

Overview

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in exon 1 of the HTT gene on chromosome 4p16.3. The mutation encodes a pathologically elongated polyglutamine (polyQ) tract within the huntingtin protein (HTT), driving a toxic gain-of-function that progressively destroys medium spiny neurons (MSNs) of the striatum and, over time, cortical and other brain regions. HD has an estimated prevalence of 5–10 per 100,000 in Western populations, with onset typically in midlife (mean ~40 years) but ranging from childhood to late adulthood depending on CAG repeat length. PMID:41349897

Genetics and Molecular Basis

Healthy individuals carry fewer than 36 CAG repeats. Alleles with 36–39 repeats display reduced penetrance; alleles with ≥40 repeats are fully penetrant. Juvenile-onset HD (before age 20) typically involves >60 CAG repeats and manifests with a more rigid, akinetic phenotype rather than the classic chorea. The CAG repeat length is the dominant determinant of age at onset, explaining ~60–70% of the variance in onset age through an inverse logarithmic relationship. However, genetic modifiers — including variants in DNA repair genes such as FAN1, MLH1, and MSH3 — influence somatic repeat instability and further modify the disease course. PMID:41349897

Mutant HTT (mHTT) is subject to proteolytic cleavage, generating N-terminal polyQ-containing fragments that are particularly toxic. These fragments aggregate into intranuclear inclusions and cytoplasmic bodies, though the relationship between inclusion bodies and toxicity remains debated; soluble oligomeric mHTT species may cause greater neuronal dysfunction than mature aggregates.

Pathophysiology

Selective Neuronal Vulnerability

The striatum is the primary site of degeneration in HD, with MSNs showing exceptional vulnerability to mHTT toxicity. Within the striatum, the indirect-pathway MSNs (enkephalinergic, D2 receptor-expressing) degenerate preferentially before direct-pathway MSNs (substance P-expressing, D1 receptor-expressing), correlating with the early clinical feature of chorea (hyperkinesia from loss of indirect pathway suppression). As disease advances, both populations degenerate and hypokinesia, dystonia, and rigidity emerge. PMID:41865324

Cellular Mechanisms

mHTT disrupts multiple cellular processes:

  • Transcriptional dysregulation: mHTT sequesters transcription factors including Sp1, NF-κB components, and CBP, reducing the expression of neuroprotective genes. BDNF transcription from cortical neurons — essential for MSN survival — is severely impaired, starving the striatum of trophic support.
  • Autophagy impairment: mHTT interferes with autophagy initiation and cargo recognition, leading to the accumulation of damaged organelles and aggregated proteins. Dysregulation of the HDAC-FOXO axis further compromises autophagic flux. PMID:41645754
  • Mitochondrial dysfunction: mHTT impairs complex I and complex II/III of the electron transport chain, reduces PGC-1α activity, and disrupts mitochondrial biogenesis. The striatum’s high energy demands make it particularly sensitive to bioenergetic failure. PMID:41865324
  • Epigenetic dysregulation: Histone deacetylases (HDACs), particularly HDAC2 and HDAC3, are upregulated in HD, compacting chromatin and silencing genes required for neuronal maintenance. PMID:41594643
  • Protein degradation failure: Decreased SREBP2 in striatal cells disrupts cholesterol homeostasis and protein degradation pathways, contributing to proteostatic stress. PMID:39313167

Clinical Features

HD presents as a clinical triad of motor, cognitive, and neuropsychiatric disturbances:

Motor: Early HD is marked by involuntary choreiform movements (chorea) — brief, dance-like jerks affecting limbs, trunk, and face. As disease progresses, chorea may plateau and eventually decline as dystonia, bradykinesia, and rigidity predominate. Dysarthria and dysphagia develop in later stages.

Cognitive: Executive dysfunction (planning, working memory, cognitive flexibility) appears early and worsens progressively. Subcortical dementia emerges with slowed processing speed. Episodic memory is relatively preserved until late stages, distinguishing HD from Alzheimer’s disease.

Neuropsychiatric: Depression affects ~40% of patients and may antedate motor onset by years. Apathy, anxiety, obsessive-compulsive behaviors, and irritability are common. Frank psychosis occurs in a minority.

Biomarkers and Disease Monitoring

Fluid biomarkers now enable disease monitoring decades before motor onset in gene-expanded individuals. Mutant HTT can be measured directly in CSF and plasma using single-molecule array (Simoa) technology, with levels correlating with proximity to predicted onset and disease stage. Neurofilament light chain (NfL) — a marker of axonal damage — rises in plasma and CSF as neurodegeneration accelerates, and has been adopted as a primary pharmacodynamic biomarker in clinical trials. PMID:41349897

Structural MRI reveals early caudate and putamen atrophy that precedes symptom onset by 10–15 years in pre-manifest gene carriers; volumetric measures of striatal atrophy correlate with motor and cognitive decline.

Therapeutic Strategies

Symptomatic Treatment

Tetrabenazine (and its deuterated form deutetrabenazine) are FDA-approved for HD chorea. These agents deplete presynaptic monoamines by inhibiting VMAT2, reducing choreiform movements. Antipsychotics (olanzapine, quetiapine) address psychiatric symptoms.

Disease-Modifying Approaches

Huntingtin-lowering strategies are the most advanced disease-modifying approaches in development:

  • Antisense oligonucleotides (ASOs): Tominersen (IONIS-HTTRx) achieved significant CSF mHTT reduction in Phase I/II, but Phase III GENERATION HD1 was halted after interim analysis showed dose-dependent worsening outcomes. Mechanistic investigations suggest that complete suppression of total (wild-type + mutant) HTT may impair essential HTT scaffold functions. Allele-specific approaches (e.g., WVE-003) that selectively target the mutant allele by exploiting SNP haplotypes are now in trials.
  • RNA interference: Subcortically delivered siRNA and miRNA targeting HTT (e.g., AMT-130 via AAV5) are in early clinical evaluation.
  • HDAC inhibition: Multiple HDAC inhibitors are under investigation to restore transcriptional programs silenced by mHTT, with particular focus on HDAC1/3 selective compounds. PMID:41594643
  • Mitochondrial support: Agents targeting PGC-1α and AMPK-mediated mitochondrial biogenesis are explored. Artemisinin compounds show promise in 3-NP (3-nitropropionic acid) HD models by modulating HMGB1/TLR4/NF-κB signaling. PMID:41865324
  • Anthraquinone compounds and other natural products with multi-target neuroprotective profiles are in preclinical investigation. PMID:41868184

Disease Relevance to Neurodegeneration Research

HD serves as a critical model system for several reasons: (1) the monogenic cause, known decades before symptom onset in gene-expanded individuals, permits pre-manifest intervention trials; (2) medium spiny neuron biology illuminates mechanisms of selective neuronal vulnerability shared with Parkinson’s disease; (3) the polyQ aggregation biology provides mechanistic parallels with polyQ diseases (SCA1, SCA3, DRPLA); and (4) the translational failure of tominersen has forced systematic re-evaluation of HTT biology, autophagy homeostasis, and patient stratification strategies that will benefit all neurodegeneration trials.

References

  • PMID:41349897 Huntingtin protein in health and Huntington’s disease: Molecular mechanisms, pathology and therapeutic strategies. Ageing Res Rev 2026.
  • PMID:41594643 Epigenetic Dysregulation in Neurodegeneration: The Role of Histone Deacetylases and Emerging Inhibitor Strategies. Biomolecules 2026.
  • PMID:41645754 Mechanistic advances in exercise-mediated regulation of autophagy dysfunction in Alzheimer’s disease. Int J Mol Med 2026.
  • PMID:41865324 Artemisinin attenuates 3-nitropropionic acid-induced neurodegeneration via HMGB1/TLR4/NF-κB modulation in a rat model of Huntington’s disease. Arch Pharm Res 2026.
  • PMID:41868184 Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases. Drug Des Devel Ther 2026.
  • PMID:41885638 Cryptoxanthin as a multitarget neuroprotective agent: mechanistic and in silico perspectives. J Pharm Pharmacol 2026.
  • PMID:39313167 Decreased SREBP2 of the striatal cell relates to disrupted protein degradation in Huntington’s disease. Brain Res 2025.
  • PMID:40123421 Dual inhibition of canonical and noncanonical PAR-1 by SCH79797 mitigates neurodegeneration in 3-NP-induced Huntington’s disease. Arch Pharm 2025.